RedHill Biopharma Announces Confirmatory Phase III Study Initiated with RHB-105 (TALICIA(TM)) for H. pylori Infection
(Thomson Reuters ONE) -
* Subject to a successful outcome and any additional regulatory feedback,
the confirmatory Phase III study (ERADICATE Hp 2) is expected to complete
the package required for a potential U.S. NDA for RHB-105, newly branded as
TALICIA((TM) )
* The two-arm, randomized, double-blind, active comparator, confirmatory Phase
III study is planned to enroll 444 non-investigated dyspepsia patients with
confirmed H. pylori infection in up to 65 clinical sites in the U.S., with a
primary endpoint of eradication of H. pyloriinfection at 42 through 70 days
after initiation of treatment
* The first Phase III study with TALICIA((TM) )(RHB-105) (ERADICATE Hp)
successfully demonstrated 89.4% efficacy in eradicating H. pylori infection
(p<0.001), supporting the potential superior efficacy of TALICIA((TM) )(RHB-
105) over current standard-of-care (SoC) therapies
* TALICIA((TM) )(RHB-105) was granted QIDP designation by the FDA under the
GAIN Act, including Fast-Track development, NDA Priority Review and extended
U.S. market exclusivity, for a total of eight years
* H. pylori bacterial infection is a major cause of chronic gastritis, peptic
ulcer disease, gastric cancer and mucosa-associated lymphoid tissue (MALT)
lymphoma and is estimated to affect over half of the adult population
worldwide
* The World Health Organization (WHO) recently published a global priority
list of 12 life-threatening multidrug-resistant bacteria, in which H.
pylori infection was classified in group 2 high-priority bacteria for which
new treatments are urgently needed
* The 2015 global and U.S. market potential for H. pylori eradication
therapies at current branded prices, were estimated at approximately $4.83
billion and $1.45 billion, respectively
TEL-AVIV, Israel and RALEIGH, N.C., June 15, 2017 (GLOBE NEWSWIRE) -- RedHill
Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the
"Company"), a specialty biopharmaceutical company primarily focused on the
development and commercialization of late clinical-stage, proprietary, orally-
administered, small molecule drugs for gastrointestinal and inflammatory
diseases and cancer, today announced the initiation of a confirmatory Phase III
study with RHB-105, newly branded as TALICIA((TM)1), for the treatment of H.
pylori infection (the ERADICATE Hp 2 study).
TALICIA((TM)) (RHB-105) is a proprietary, fixed-dose, oral combination therapy
of two antibiotics and a proton pump inhibitor (PPI) in an all-in-one oral
capsule for the eradication of H. pylori infection.
The two-arm, randomized, double-blind, active comparator confirmatory Phase III
ERADICATE Hp 2 study will compare TALICIA((TM)) (RHB-105) against a dual therapy
amoxicillin and omeprazole regimen at equivalent doses. The study is planned to
enroll 444 non-investigated dyspepsia patients with confirmed H.
pylori infection in up to 65 clinical sites in the U.S. Subjects will be
randomized in a 1:1 ratio to receive four capsules, three times daily, of either
TALICIA((TM)) (RHB-105) or the active comparator, for a period of 14 days.
Subjects will be assessed for the study's primary endpoint of eradication of H.
pyloriinfection at 42 through 70 days after initiation of treatment.
Subject to its successful outcome and any additional regulatory feedback, the
confirmatory Phase III study, along with the results from the successfully
completed first Phase III study with TALICIA((TM)) (RHB-105) (the ERADICATE Hp
study) and data from the completed supportive PK program, are expected to
support a potential U.S. New Drug Application (NDA) for TALICIA((TM)) (RHB-105).
The first Phase III study with TALICIA((TM)) (RHB-105) successfully met its
protocol-defined mITT primary endpoint of superiority over historical standard-
of-care (SoC) eradication rate of 70%, with high statistical significance
(p<0.001). The study results demonstrated 89.4% efficacy in eradicating H.
pylori infection with TALICIA((TM)) (RHB-105). Notably, the 89.4% efficacy in
eradicating H. pylori infection with TALICIA((TM))(RHB-105) was also superior to
subsequent open-label treatment with SoC therapies of patients in the placebo
arm of the ERADICATE Hp study, which demonstrated 63% eradication rate in the
mITT population (p=0.006), further supporting the potential efficacy of
TALICIA((TM)) (RHB-105) as a treatment forH. pylori infection. Treatment with
TALICIA((TM)) (RHB-105) appeared to be safe and well tolerated.
TALICIA((TM)) (RHB-105) was granted Qualifying Infectious Disease Product (QIDP)
designation by the U.S. Food and Drug Administration (FDA), providing a Fast-
Track development pathway, as well as NDA Priority Review status, potentially
leading to a shorter NDA review time by the FDA, if filed. If approved,
TALICIA((TM)) (RHB-105) is entitled to receive, thanks to its QIDP status, an
additional five years of U.S. market exclusivity, in addition to the standard
exclusivity period, for a total of 8 years of U.S. market exclusivity.
RedHill is pursuing with TALICIA((TM)) (RHB-105) an indication of first-line
treatment of H. pylori infection, regardless of ulcer status, a significantly
broader indication than current standard treatments for H. pylori, which are
typically indicated only for patients with active or recent history of duodenal
ulcer disease. If approved, TALICIA((TM)) (RHB-105) may be the first H.
pylori eradication therapy in the U.S. to target this broader indication, which
would significantly expand the potential patient population for this drug
candidate.
H. pylori bacterial infection is a major cause of chronic gastritis, peptic
ulcer disease, gastric cancer and mucosa-associated lymphoid tissue (MALT)
lymphoma. H. pylori infection is estimated to affect over half of the adult
population worldwide(2). The growing resistance of the H. pylori bacteria to
metronidazole and clarithromycin has resulted in increasing failure rates of
current SoC for H. pylori eradication, reaching an estimated 30%(3). Despite the
strong unmet medical need, no new drug has been approved by the FDA for this
indication in over a decade. The World Health Organization (WHO) recently
published a global priority list of 12 life-threatening multidrug-resistant
bacteria, in which H. pylori infection was classified as a high-priority
bacteria for which new treatments are urgently needed(4).
The 2015 global and U.S. market potential for H. pylori eradication therapies at
branded prices, were estimated at approximately $4.83 billion and $1.45 billion,
respectively, and could potentially grow with increasing awareness of the health
risks associated with H. pylori infection and the benefits of its
eradication(5).
The confirmatory Phase III ERADICATE Hp 2 study with TALICIA((TM)) (RHB-105)
will be registered on www.ClinicalTrials.gov, a web-based service of the U.S.
National Institutes of Health, which provides access to information on publicly
and privately supported clinical studies.
About TALICIA((TM)) (RHB-105):
RHB-105, newly branded as TALICIA((TM)), is a new and proprietary fixed-dose
oral combination therapy of two antibiotics and a proton pump inhibitor (PPI) in
an all-in-one oral capsule with a planned indication for the treatment of H.
pylori infection. H. pylori bacterial infection is a major cause of chronic
gastritis, peptic ulcer disease, gastric cancer and mucosa-associated lymphoid
tissue (MALT) lymphoma. A first Phase III study with TALICIA((TM)) (RHB-105)
(the ERADICATE Hp study) was completed in the U.S. with positive results. The
study demonstrated an overall success rate of 89.4% in eradicating H. pylori,
and met its protocol-defined primary endpoint of superiority in eradication
of H. pylori infection over historical standard-of-care efficacy levels of 70%,
with high statistical significance (p<0.001). A confirmatory Phase III study
(ERADICATE Hp 2 study) has been initiated in the U.S. Additional studies may be
required, subject to FDA review. TALICIA((TM)) (RHB-105) has been granted
Qualifying Infectious Disease Product (QIDP) designation by the FDA, providing a
Fast-Track development pathway, as well as NDA Priority Review status,
potentially leading to a shorter NDA review time by the FDA, if filed. If
approved, TALICIA((TM)) (RHB-105) will also receive an additional five years of
exclusivity, in addition to the standard exclusivity period, for a total of 8
years of U.S. market exclusivity.
About RedHill Biopharma Ltd.:
RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) is a
specialty biopharmaceutical company headquartered in Israel, primarily focused
on the development and commercialization of late clinical-stage, proprietary,
orally-administered, small molecule drugs for the treatment of gastrointestinal
and inflammatory diseases and cancer. RedHill promotes two gastrointestinal
products in the U.S. - Donnatal(®), a prescription oral adjunctive drug used in
the treatment of IBS and acute enterocolitis, and EnteraGam(®), a medical food
intended for the dietary management, under medical supervision, of chronic
diarrhea and loose stools. RedHill's clinical-stage pipeline includes:
(i) TALICIA((TM)) (RHB-105) - an oral combination therapy for the treatment
of Helicobacter pylori infection with successful results from a first Phase III
study and an ongoing confirmatory Phase III study; (ii) RHB-104 -an oral
combination therapy for the treatment of Crohn's disease with an ongoing first
Phase III study, a completed proof-of-concept Phase IIa study for multiple
sclerosis and QIDP status for nontuberculous mycobacteria (NTM) infections;
(iii) BEKINDA(®) (RHB-102) - a once-daily oral pill formulation of ondansetron
with successful top-line results in a Phase III study for acute gastroenteritis
and gastritis and an ongoing Phase II study for IBS-D; (iv) RHB-106 - an
encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.;
(v) YELIVA(®) (ABC294640) - a Phase II-stage, orally-administered, first-in-
class SK2 selective inhibitor targeting multiple oncology, inflammatory and
gastrointestinal indications; (vi) MESUPRON - a Phase II-stage first-in-class,
orally-administered protease inhibitor, targeting pancreatic cancer and other
solid tumors and (vii) RIZAPORT(®) (RHB-103) - an oral thin film formulation of
rizatriptan for acute migraines, with a U.S. NDA currently under discussion with
the FDA and marketing authorization received in two EU member states under the
European Decentralized Procedure (DCP). More information about the Company is
available at: www.redhillbio.com.
This press release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. Such statements may be
preceded by the words "intends," "may," "will," "plans," "expects,"
"anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes,"
"potential" or similar words. Forward-looking statements are based on certain
assumptions and are subject to various known and unknown risks and
uncertainties, many of which are beyond the Company's control, and cannot be
predicted or quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements. Such risks
and uncertainties include, without limitation, risks and uncertainties
associated with (i) the initiation, timing, progress and results of the
Company's research, manufacturing, preclinical studies, clinical trials, and
other therapeutic candidate development efforts; (ii) the Company's ability to
advance its therapeutic candidates into clinical trials or to successfully
complete its preclinical studies or clinical trials; (iii) the extent and number
of additional studies that the Company may be required to conduct and the
Company's receipt of regulatory approvals for its therapeutic candidates, and
the timing of other regulatory filings, approvals and feedback; (iv) the
manufacturing, clinical development, commercialization, and market acceptance of
the Company's therapeutic candidates; (v) the Company's ability to successfully
market Donnatal(® )and EnteraGam(®), (vi) the Company's ability to establish and
maintain corporate collaborations; (vii) the Company's ability to acquire
products approved for marketing in the U.S. that achieve commercial success and
build its own marketing and commercialization capabilities; (viii) the
interpretation of the properties and characteristics of the Company's
therapeutic candidates and of the results obtained with its therapeutic
candidates in research, preclinical studies or clinical trials; (ix) the
implementation of the Company's business model, strategic plans for its business
and therapeutic candidates; (x) the scope of protection the Company is able to
establish and maintain for intellectual property rights covering its therapeutic
candidates and its ability to operate its business without infringing the
intellectual property rights of others; (xi) parties from whom the Company
licenses its intellectual property defaulting in their obligations to the
Company; and (xii) estimates of the Company's expenses, future revenues capital
requirements and the Company's needs for additional financing; (xiii)
competitive companies and technologies within the Company's industry. More
detailed information about the Company and the risk factors that may affect the
realization of forward-looking statements is set forth in the Company's filings
with the Securities and Exchange Commission (SEC), including the Company's
Annual Report on Form 20-F filed with the SEC on February 23, 2017. All forward-
looking statements included in this Press Release are made only as of the date
of this Press Release. We assume no obligation to update any written or oral
forward-looking statement unless required by law.
_____________________________
(1) TALICIA((TM)) is an investigational new drug, not available for commercial
distribution.
(2) Hunt, R. H., et al. "Helicobacter pylori in developing countries." World
Gastroenterology Organisation Global Guidelines (2010): 1-15.
(3) Malfertheiner P. et al. Management of Helicobacter pylori infection - the
Maastricht IV/ Florence Consensus Report, Gut 2012;61:646-664.
(4) WHO report - Global priority list of antibiotic-resistant bacteria to guide
research, discovery, and development of new
antibiotics: http://www.who.int/medicines/publications/global-priority-list-
antibiotic-resistant-bacteria/en/
(5 )Jerry Rosenblatt, Ph.D., a member of RedHill's Advisory Board and Partner at
Foster Rosenblatt, RedHill Biopharma press release: RedHill Biopharma's Investor
Webcast Forum Provides Update on the RHB-105 Phase III Program and Potential H.
Pylori Eradication Market, May 18, 2015.
Company contact:
Adi Frish
Senior VP Business Development &
Licensing
RedHill Biopharma
+972-54-6543-112
adi(at)redhillbio.com
IR contact (U.S.):
Marcy Nanus
Senior Vice President
The Trout Group
+1-646-378-2927
Mnanus(at)troutgroup.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: RedHill Biopharma Ltd. via GlobeNewswire
Datum: 15.06.2017 - 14:00 Uhr
Sprache: Deutsch
News-ID 548170
Anzahl Zeichen: 17625
contact information:
Town:
Tel-Aviv
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 189 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"RedHill Biopharma Announces Confirmatory Phase III Study Initiated with RHB-105 (TALICIA(TM)) for H. pylori Infection"
steht unter der journalistisch-redaktionellen Verantwortung von
RedHill Biopharma Ltd. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
